Results 1 to 10 of about 2,943 (200)

Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone

open access: yesIDCases, 2022
Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B.
Luis A. Marcos   +3 more
doaj   +3 more sources

The cost-effectiveness of tafenoquine following screening with STANDARD™ G6PD screening for the treatment of vivax malaria in the Brazilian Public Health SystemResearch in context [PDF]

open access: yesThe Lancet Regional Health. Americas
Summary: Background: Vivax malaria requires radical cure to clear both the blood-stage and liver-stage parasites. Brazil, like most endemic countries, has been prescribing a 7-day primaquine regimen for radical cure without testing for glucose-6 ...
Henry Maia Peixoto   +8 more
doaj   +2 more sources

Tafenoquine lactation pharmacokinetics: a pilot study [PDF]

open access: yesMalaria Journal
Background Radical cure with an 8-aminoquinoline is required to prevent relapses from Plasmodium vivax. Single-dose treatment with tafenoquine offers significant advantages over primaquine, but the amount of tafenoquine excreted in breastmilk is unknown.
Mary Ellen Gilder   +14 more
doaj   +2 more sources

Effectiveness of tafenoquine and primaquine for radical cure of Plasmodium vivax: a meeting report from dissemination of results of the EFFORT trial to stakeholders in Pakistan [PDF]

open access: yesMalaria Journal
Plasmodium vivax remains the predominant cause of malaria in Pakistan, accounting for approximately 85% of confirmed cases. The recurrent nature of P. vivax, driven by dormant liver-stage hypnozoites, poses a major obstacle to malaria control.
Bushra Qurashi   +17 more
doaj   +2 more sources

Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi [PDF]

open access: yesParasites & Vectors
Background Equine piroplasmosis (EP) is a tick-borne disease of equids caused by the intraerythrocytic apicomplexan parasites Theileria equi, Babesia caballi and the recently identified Theileria haneyi.
Natalia N. Cardillo   +5 more
doaj   +2 more sources

Development of a Plasmodium vivax malaria model for evaluating the effects of control strategies on the malaria burden in Democratic People’s Republic of Korea [PDF]

open access: yesFrontiers in Public Health
BackgroundPlasmodium vivax malaria has been one of the most troublesome diseases in the Democratic People’s Republic of Korea (DPRK). Given that a majority of malaria cases are concentrated near the demilitarized zone, concerted elimination efforts from ...
Hye Seong   +4 more
doaj   +2 more sources

Perceptions of shorter radical cure Plasmodium vivax treatment regimens and their implementation: a qualitative study among stakeholders in Cambodia [PDF]

open access: yesMalaria Journal
Background Plasmodium vivax malaria remains a significant public health concern in the Asia Pacific, the Americas, and the Horn of Africa. Shorter, more effective treatment options for P.
Sarah A. Cassidy-Seyoum   +12 more
doaj   +2 more sources

Strategic resource allocation for malaria elimination in endemic settings: a systematic review of cost-effectiveness evidence [PDF]

open access: yesFrontiers in Public Health
IntroductionMalaria remains a significant global health burden, especially in endemic regions where efficient use of limited resources is critical.
Misra Helma Firdaus   +6 more
doaj   +2 more sources

Piloting the options assessment toolkit with national malaria programme leaders from the Asia–Pacific countries: a meeting report [PDF]

open access: yesMalaria Journal
Plasmodium vivax malaria remains a major challenge in the Asia–Pacific region, where National Malaria Programmes (NMPs) will need to determine optimal radical cure strategies given the availability of novel options, such as high-dose primaquine and ...
Manash Shrestha   +40 more
doaj   +2 more sources

Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria [PDF]

open access: yesMalaria Journal
A single 300 mg dose of tafenoquine (an 8-aminoquinoline), in combination with a standard 3-day course of chloroquine, is approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥ 16 years ...
Raman Sharma   +12 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy